Sutro Biopharma, Inc. (STRO) stock

STRONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30

$10.26+0.09 (+0.88%)

Close on Nov 11, 2026Market cap $170.12MP/E –Yield –

Sutro Biopharma price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Sutro Biopharma's price to book ratio was 2.0× on Apr 30, 2025, against 1.4× a year earlier. Over the last 5 years it ranged from 0.9× to 3.5×, with a median of 1.9×.

Price to Book Ratio at the end of each year

Period	Period end	Value	Change (pts)
2025	Apr 30, 2025	2.0×	+0.6
2024	Dec 31, 2024	1.4×	−1.0
2023	Dec 29, 2023	2.3×	+0.4
2022	Dec 30, 2022	1.9×	−0.5
2021	Dec 31, 2021	2.4×	−1.0
2020	Dec 31, 2020	3.4×	+1.1
2019	Dec 31, 2019	2.3×	–

Where these numbers come from

Parsed from the XBRL in Sutro Biopharma's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-10 reverse split on Dec 3, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing